INTRODUCTION
============

The transformation related protein p53 gene, *Trp53*, is the most frequently mutated gene in human cancer, altered in approximately 50% of human malignancies ([@b4-0050397]). The p53 nuclear phosphoprotein functions as a transcription factor that responds to cellular stress by initiating multiple signaling pathways. The p53 response varies across cell and tissue types, and involves a spectrum from transient cell cycle arrest to senescence and apoptosis ([@b25-0050397]). Mice deficient for p53 generally develop normally, but are predisposed to cancer at a young age ([@b6-0050397]; [@b11-0050397]).

The site-specific recombinases Cre and Flp allow for spatially and temporally regulated mutation of a target gene in the somatic tissues of mice ([@b3-0050397]). Conditional recombination of *p53* using the Cre-*loxP* system has been utilized to delete or mutate p53 in a tissue-specific manner or to delete p53 at a specific time during development ([@b5-0050397]). This technology has led to the development of multiple mouse models of primary cancer ([@b17-0050397]; [@b15-0050397]; [@b12-0050397]; [@b13-0050397]; [@b18-0050397]). Genetically engineered mouse models (GEMMs) might offer an advantage over xenograft and chemically induced cancer models by providing an opportunity to study mechanisms of autochthonous cancer development and response to treatment in an anatomically restricted manner in mice that are neither tumor-prone nor immunosuppressed ([@b23-0050397]). However, most GEMMs use Cre-*loxP* technology to initiate cancer, limiting the availability of Cre recombinase to modify genes in tumor stromal cells.

Because Cre and Flp recombine distinct DNA target sites, *loxP* and *FRT*, respectively ([@b3-0050397]), these two highly efficient site-specific recombinase systems (Cre-*loxP* and Flp-*FRT*) have been used to create genetically engineered mice with a targeting construct with a removable positive selection cassette ([@b19-0050397]). More recently, dual recombinase technology was used to sequentially delete *p53* and activate the *Kras* oncogene, revealing the importance of timing of *Kras* and *p53* mutations in tumorigenesis ([@b28-0050397]). Despite the growing abundance of *loxP*-flanked ('floxed') alleles and tissue-specific Cre drivers, the Flp-*FRT* system has been utilized less frequently than Cre-*loxP* to modify genes in the somatic tissues in mice. Generating additional *FRT*-flanked ('frted') alleles will enable dual recombinase technology so that distinct gene mutations can be directed to different cell types by Cre and Flp recombinases. Here, we generated *p53^FRT^* mice in which the endogenous *p53* allele is flanked by *FRT* sites so that it can be deleted by Flp recombinase.

RESULTS
=======

Generation of *p53^FRT^* mice
-----------------------------

To generate a frted p53 mouse, we constructed a targeting vector in which exons 2 through 6 of *p53* genomic DNA are flanked by *FRT* sites ([Fig. 1A](#f1-0050397){ref-type="fig"}). Exons 2--6 encode for the DNA-binding domain that is required for p53-dependent tumor suppression ([@b2-0050397]). The 5′ *FRT* site was inserted between exons 1 and 2, and a *loxP*-flanked (floxed) PGK-*neo* cassette (*neo*) followed by a 3′ *FRT* site was inserted between exons 6 and 7. A PGK-diphtheria toxin A (*DTA*) cassette was placed following exon 11 as a negative selectable marker. The targeting vector was linearized and electroporated into embryonic stem (ES) cells. Following selection by G418, two out of 800 colonies had correctly undergone homologous recombination as demonstrated by PCR ([Fig. 1B](#f1-0050397){ref-type="fig"}). Successful homologous recombination of the *p53^FRT-neo^* allele into the endogenous *p53* locus was confirmed by Southern blot. As shown in [Fig. 1A](#f1-0050397){ref-type="fig"} and [1C](#f1-0050397){ref-type="fig"}, a *Sca*I-digested DNA fragment of 6.7 kb, which includes genomic DNA outside the targeting construct, was detected in these two ES cell clones using probes binding either *neo* or exon 11 of *p53*. ES cell line 8--8B was used to derive germline transmitting chimeric mice. Male chimeric mice were then bred to *Meox2-Cre* females to delete the floxed PGK-*neo* cassette in germline cells. Germline transmission of the targeted allele after deletion of the *neo* cassette (*p53^FRT^* allele as shown in [Fig. 1A](#f1-0050397){ref-type="fig"}) was confirmed by PCR ([Fig. 1D](#f1-0050397){ref-type="fig"}).

![**Generation of *p53^FRT/FRT^* mice by gene targeting.** (A) Schematic representation of the wild-type *p53* locus, the targeting construct, and the *p53^FRT-neo^*, *p53^FRT^* and *p53^Δ2--6^* alleles. The 5′ *FRT* site (yellow triangle) was inserted between exons 1 and 2, whereas the 3′ *FRT* site (yellow triangle) and a *loxP*-flanked (red diamonds) PGK-*neo* cassette (*neo*) were inserted between exons 6 and 7 of *p53*. A PGK-*DTA* (DTA) cassette was placed following exon 11 as a negative selectable marker. (B) PCR amplicons including the 5′ *FRT* site (292 bp) as well as the PGK-*neo* cassette (2.5 kb) were detected in two ES cell clones (7--9H and 8--8B) electroporated with the targeting vector, whereas only one amplicon of the wild-type *p53* allele (258 bp) was present in ES cells without transfection (WT). (C) Genomic DNA from aforementioned ES cells was digested by *Sca*I and hybridized with DNA probes that bind to either the PGK-*neo* cassette or *p53* exon 11. A DNA fragment of ∼6.7 kb that includes the PGK-*neo* cassette was detected in ES cells 7--9H and 8--8B using either probe, but was absent in WT ES cells. By contrast, a *Sca*I-digested fragment of ∼5 kb from the WT *p53* allele was detected in all ES cells using the probe binding to exon 11. (D) Transmission of the *p53^FRT^* allele was shown by PCR using DNA extracted from tails of *p53^FRT/FRT^*, *p53^FRT/+^* and WT mice. PCR amplicons including the 5′ *FRT* site (292 bp) as well as the 3′ *FRT* site and recombined *loxP* site (685 bp) were detected in *p53^FRT/FRT^* and *p53^FRT/+^* mice, but were absent in WT littermates.](DMM009084F1){#f1-0050397}

Characterization of *p53^FRT^* MEFs
-----------------------------------

To study FlpO-mediated recombination of the *p53^FRT^* allele, mouse embryonic fibroblasts (MEFs) were isolated from *p53^FRT^* mice and infected with an adenovirus expressing FlpO (Ad-FlpO) or eGFP (Ad-eGFP). FlpO is a Flp recombinase with codons optimized for recombination in mammalian systems ([@b22-0050397]). Successful recombination of the *p53^FRT^* allele was confirmed by PCR ([Fig. 2A](#f2-0050397){ref-type="fig"}). Doxorubicin is a commonly used chemotherapeutic that is known to induce p53-mediated cell cycle arrest at the G1 checkpoint by increasing p21 protein levels ([@b1-0050397]). To demonstrate that recombination of the *p53^FRT^* gene by FlpO impairs the p53 response to genotoxic stress, MEFs infected with Ad-FlpO or Ad-eGFP were treated with 0.5μg/ml doxorubicin for 18 hours. Protein levels measured by western blot demonstrated decreased p53 in *p53^FRT/−^* MEFs infected with Ad-FlpO when compared with *p53^FRT/−^* MEFs infected with Ad-eGFP ([Fig. 2B](#f2-0050397){ref-type="fig"}). In addition, FlpO-mediated recombination decreased p21 induction after exposure to doxorubicin. Levels of p53 and p21 in Ad-FlpO-infected *p53^FRT/−^* MEFs were slightly greater than control *p53*-null (*p53^−/−^*) MEFs, which probably reflects incomplete infection of the MEFs with adenovirus.

Primary mammalian cells such as MEFs have a limited life span in vitro owing to p53-mediated senescence and are transformed by loss of p53 ([@b10-0050397]). We investigated whether cell-culture-induced senescence occurs in *p53^FRT/−^* MEFs after FlpO-mediated recombination by assessing population doubling of cells in vitro. Similar to *p53^−/−^* MEFs, *p53^FRT/−^* MEFs infected with Ad-FlpO did not show p53-mediated senescence and proliferated faster than *p53^FRT/−^* MEFs infected with Ad-eGFP ([Fig. 2C](#f2-0050397){ref-type="fig"}). Additionally, FlpO-recombined *p53^FRT/−^* MEFs were found to be genetically unstable compared with *p53^WT^* MEFs, as demonstrated by their markedly increased DNA content at later passages ([Fig. 2D](#f2-0050397){ref-type="fig"}).

![**Characterization of *p53^FRT^* MEFs.** (A) PCR primers flanking the 5′ *FRT* site and the recombined *FRT* site (Δ2--6) demonstrate recombination of the *p53^FRT^* allele in *p53^FRT/−^*MEFs infected with 100 MOI FlpO-expressing adenovirus (Ad-FlpO), but not *p53^FRT/−^* MEFs infected with eGFP-expressing adenovirus (Ad-eGFP). (B) Western blot of passage 5 MEFs treated with 0.5 μg/ml doxorubicin for 18 hours after infection with Ad-FlpO or Ad-eGFP. (C) 3T3 protocol on *p53^−/−^* and *p53^FRT/−^*MEFs infected with 100 MOI Ad-FlpO and *p53^FRT/−^* MEFs infected with 100 MOI Ad-eGFP. (D) Relative DNA content based on propidium iodide staining measured by flow cytometry of passage 4 and passage 10 MEFs infected with 100 MOI Ad-FlpO.](DMM009084F2){#f2-0050397}

Generation of FlpO-driven tumors
--------------------------------

To study Flp-mediated recombination of the *p53^FRT^* allele in vivo, we crossed *p53^FRT^* mice with mice carrying a Flp-activated allele of oncogenic *Kras* to generate *FSF-Kras^G12D/+^; p53^FRT/FRT^* (*KP^FRT^*) compound conditional mutant mice. It has been shown that activation of *Kras^G12D^* and deletion of *p53* in *LSL-Kras^G12D/+^; p53^FL/FL^* (*KP^FL^*) mice via intramuscular (IM) and intranasal (IN) infection with Ad-Cre is sufficient to initiate high-grade soft-tissue sarcomas and lung adenocarcinomas ([@b12-0050397]; [@b13-0050397]). However, activation of *Kras^G12D^* via IM Ad-Cre infection does not initiate soft-tissue sarcomas and IN Ad-Cre infection generates only lung adenomas and low-grade adenocarcinomas. We infected *KP^FRT^* mice with IM and IN Ad-FlpO, and extremity sarcomas and high-grade lung adenocarcinomas developed as early as 8 weeks after infection ([Fig. 3A--D](#f3-0050397){ref-type="fig"}). The time frame of tumor development was similar to that of tumors generated in *KP^FL^* mice by Ad-Cre infection ([@b12-0050397]; [@b13-0050397]). Although *FSF-Kras^G12D/+^* mice can also develop lung tumors, the tumors are low grade ([@b28-0050397]). *Kras^G12D/+^* lung tumors have an average tumor volume doubling time of approximately 35 days ([@b21-0050397]). By contrast, lung tumors from *KP^FRT^* mice had a doubling time of approximately 2 weeks ([Fig. 3E,F](#f3-0050397){ref-type="fig"}), which was similar to that of lung tumors generated in *KP^FL^* mice following Ad-Cre infection ([@b14-0050397]; [@b21-0050397]).

DISCUSSION
==========

Human cancers develop in a complex environment composed of blood vessels, fibroblasts and immune cells. The tumor microenvironment has been shown to contribute to all of the hallmarks of cancer ([@b9-0050397]). Primary mouse models of cancer driven by site-specific recombinases develop within the native microenvironment in immunocompetent mice. A number of studies have demonstrated that genetically engineered mouse models could more accurately recapitulate the tumor stroma and microenvironment of human cancer than xenograft models in immunocompromised mice ([@b20-0050397]; [@b8-0050397]; [@b16-0050397]). In addition, the response of these primary mouse cancer models to conventional and novel therapies has been shown to closely model the response of human cancers in clinical trials ([@b24-0050397]). Dual recombinase technology will enable further examination of the role of the tumor microenvironment in primary tumors ([Fig. 4](#f4-0050397){ref-type="fig"}).

Interestingly, a mouse with deletion of the first six exons of *p53* was previously reported to express a truncated RNA capable of coding for the C-terminus of the p53 protein that can be detected only after in vitro translation ([@b27-0050397]). When combined with one wild-type copy of *p53* (*p53^m/+^*), this mutant allele (m) leads to a gain of p53 function and early-aging associated phenotypes. However, *p53^m/m^* mice phenocopy *p53^−/−^* mice. We have looked for a truncated p53 protein in *p53^FRT/−^* MEFs infected with Ad-FlpO by western blot by using an antibody against the full-length p53 protein. However, we were unable to detect the truncated protein. This might be due to lack of antibody specificity for the C-terminal epitope or because the level of truncated p53 protein in mouse cells is below the detection limit by western blot, similar to that found in *p53^m/m^* mice ([@b27-0050397]). Regardless of whether the truncated p53 protein is expressed, this recombined allele lacks the ability to suppress tumor development. In addition, a *FRT*-flanked p53 mouse has been generated by Exelixis. In this mouse, exons 2--10 are flanked by *FRT* sites. This allele has been used to generate primary mouse lung tumors in combination with the *LSL-Kras^G12D^* allele using an adenovirus expressing both Cre and Flp ([@b24-0050397]). However, to our knowledge, our study is the first to use a *p53^FRT^* allele to generate lung adenocarcinomas and soft-tissue sarcomas with Flp-mediated recombination alone.

In summary, we have generated a conditional p53 mouse allele regulated by Flp recombinase. When used in combination with the *FSF-Kras^G12D^* allele, the *p53^FRT^* mouse can be used to generate primary sarcomas and lung cancers with Flp recombinase. When combined with the growing number of *loxP*-flanked alleles and tissue-specific Cre drivers, this novel mouse model will enable dual recombinase technology to be employed to investigate the mechanism by which stromal cells contribute to cancer development, progression, and response to therapy.

![**Generation of primary cancers in *FSF-Kras^G12D/+^; p53^FRT/FRT^* mice by Flp recombinase.** (A) Intramuscular injection of Ad-FlpO into *FSF-Kras^G12D/+^; p53^FRT/FRT^* mice caused soft tissue sarcomas at the site of injection in the lower extremity 2 months post-injection. (B) Sections of the sarcomas were stained with hematoxylin and eosin, and show high-grade spindle cells. (C) Intranasal infection of Ad-FlpO into *FSF-Kras^G12D/+^; p53^FRT/FRT^* mice caused lung adenocarcinomas 2 months post-infection. (D) Higher magnification of lung tumors demonstrates pleomorphic nuclei, prominent nucleoli and nuclear molding characteristic of high-grade adenocarcinoma. Scale bars: 100 μm. (E) Relative tumor volume measured by micro-CT of lung cancers from *FSF-Kras^G12D/+^; p53^FRT/FRT^* mice. A total of three tumors were contoured from two mice. Micro-CT scans were performed at 8 weeks and 10 weeks after infection with Ad-FlpO. (F) Doubling time in days for lung cancers in *FSF-Kras^G12D/+^; p53^FRT/FRT^* mice. Data are presented as mean ± s.e.m.](DMM009084F3){#f3-0050397}

METHODS
=======

Mouse strains
-------------

All animal procedures for this study were approved by the Institutional Animal Care and Use Committee (IACUC) at Duke University. *FSF-Kras^G12D^* and *p53^−/−^* mice were kindly provided by Tyler Jacks and were described previously ([@b11-0050397]; [@b28-0050397]). *Meox2-Cre* mice were obtained from Jackson Laboratory ([@b26-0050397]).

![**Rationale for dual recombinase technology.** (A) Ad-Cre infection generates tumors by expressing Cre recombinase in tumor-initiating cells. However, in this model, Cre recombinase cannot be utilized to selectively recombine additional floxed alleles in stromal cells. (B) Dual recombinase technology combines Ad-Flp infection with a tissue-specific Cre driver that recombines floxed alleles in stromal cells. For example, Tie2-Cre recombines floxed alleles in endothelial cells and macrophages. Tumors can be initiated by Flp-mediated activation of oncogenes and deletion of frted tumor suppressor genes. This approach enables recombination of floxed alleles in stromal cells expressing Cre recombinase only.](DMM009084F4){#f4-0050397}

Construction of the *p53^FRT-neo^* targeting vector and generation of mice
--------------------------------------------------------------------------

Genomic DNA of the mouse *p53* gene was provided by Tyler Jacks and was used to make the targeting construct. We used an *Nde*I site in intron 1 and a *Bam*HI site in intron 6 to insert a single *FRT* site before exon 2 and exon 7, respectively. A *loxP*-flanked PGK-*neo* cassette was inserted into intron 6 before the *FRT* site as a positive selectable marker and a PGK-*DTA* cassette was inserted into the targeting vector after exon 11 as a negative marker. The targeting vector was linearized with *Pac*I and electroporated into ES cells using standard conditions. Diagnostic PCR was performed to identify ES clones with successful homologous recombination using primers flanking the PGK-*neo* cassette (sense primer 5′-TGCTCCTGCCGAGAAAGTAT-3′ and anti-sense primer 5′-CACCATGAGACAGGGTCTTG-3′) and primers flanking the 5′ *FRT* site (sense 5′-CAAGAGAACTGTGCCTAAGAG-3′ and anti-sense 5′-CTTTCTAACAGCAAAGGCAAGC-3′). Two out of 800 ES cells were positive at both sites. Genomic DNA of these two clones was digested by *Sca*I and successful homologous recombination of the *p53^FRT-neo^* allele was determined by Southern blot using probes binding to either *neo* or exon 11. One clone was used to derive male germline *p53^FRT-neo^* chimeras, which were bred with *Meox2-Cre* females to delete the floxed *neo* in the germ line. Deletion of *neo* was verified by PCR using primers flanking the recombined *loxP* site and 3′ *FRT* site: sense 5′-TGAGCCAC-CCGAGGTCTGTAATTT-3′ and anti-sense 5′-ACTCGTGG-AACAGAAACAGGCAGA-3′. Both *FRT* sites, the recombined *loxP* site and all exons of *p53*, including intron-exon splice sites, were sequenced to confirm that no mutations were present in *p53^FRT/FRT^* mice. These mice will be donated to Jackson Laboratory.

PCR genotyping
--------------

Tissue genotyping and amplification conditions were as follows: *p53^FRT^* allele, *5*′ *FRT* sense primer 5′-CAAGAGAACTGTGCCT-AAGAG-3′ and 5′ *FRT* anti-sense primer 5′-CTTTCTAA-CAGCAAAGGCAAGC-3′, cycling at 94°C for 30 seconds, 57°C for 30 seconds, 72°C for 40 seconds; recombined *p53^Δ2--6^* allele, 5′ *FRT* sense primer 5′-CAAGAGAACTGTGCCTAAGAG-3′ and 3′ *FRT* anti-sense primer 5′-ACTCGTGGAACAGAAACAGG-CAGA-3′, cycling at 94°C for 30 seconds, 55°C for 45 seconds, 72°C for 2 minutes.

In vitro recombination in MEFs
------------------------------

Primary MEFs were isolated from pregnant female mice between 12.5 and 14.5 days of gestation. PCR genotyping was performed on DNA isolated from the embryo heads. MEFs were cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, 2-mercaptoethanol, glutamine and non-essential amino acids. Passage 4 MEFs were infected with 100 multiplicity of infection (MOI) Ad5CMVeGFP or Ad5CMVFlpO (University of Iowa Gene Transfer Vector Core, Iowa City, IA) in MEF media for 24 hours. Recombination was confirmed by PCR.

Immunoblotting
--------------

Induction of p53 and p21 in MEFs was achieved by treatment of passage 5 MEFs with 0.5 μg/ml doxorubicin (Sigma-Aldrich, St Louis, MO) for 18 hours. MEFs were washed with PBS and protein was harvested with RIPA buffer (Sigma-Aldrich, St Louis, MO). A total of 25 μg of total protein were loaded for electrophoresis into 10% sodium dodecyl sulfate polyacrylamide gels. Separated proteins were transferred to a PVDF membrane. Membranes were blocked with 5% nonfat dry milk in TBS with 0.1% Tween 20. Protein levels were detected using antibodies against p53 (IMX25 clone, Vector Labs, Burlingame, CA; final dilution 1:1000), p21 (F-5 clone, Santa Cruz, Santa Cruz, CA; final dilution 1:1000) and actin (C4 clone, BD Biosciences, Franklin Lakes, NJ; final dilution 1:5000) followed by secondary goat anti-mouse IgG horseradish-peroxidase-conjugated antibody (Invitrogen, Carlsbad, CA; final dilution 1:2000). Bands were visualized using ECL Plus western blotting detection reagents (Amersham, Pittsburgh, PA).

3T3 senescence
--------------

Primary MEFs were plated at a density of 300,000 cells per 6-cm dish and allowed to grow for 3 days. Cells were harvested, counted using a Z1 Coulter particle counter (Beckman Coulter, Brea, CA) and re-plated at 300,000 cells per 6-cm dish for a total of ten passages. DNA content of early and late passage MEFs was measured after staining with 50 μg/ml propidium iodide by flow cytometry using a FACSCanto analyzer (Becton Dickinson, UK).

Generation of primary tumors
----------------------------

Primary soft-tissue sarcomas and lung adenocarcinomas were generated as described previously by infecting *KP^FRT^* mice with IM or IN Ad5CMVFlpO ([@b13-0050397]; [@b7-0050397]). Briefly, 25 μl Ad5CMVFlpO (6×10^10^ PFU/ml) was incubated in 600 μl minimum essential media (Sigma-Aldrich, St Louis, MO) with 3 μl 2 M CaCl~2~ (Sigma-Aldrich, St Louis, MO) for 15 minutes to form calcium phosphate precipitates. A total of 50 μl precipitated virus per mouse was injected intramuscularly to generate sarcomas, or 30 μl precipitated virus followed by 30 μl media was administered via IN inhalation to initiate lung tumors.

###### RESOURCE IMPACT

**Background**

Cre recombinase has been used to develop many mouse models of primary cancer through enabling deletion of tumor suppressors and activation of oncogenes in somatic tissues of mice in a spatially and temporally restricted manner. The primary tumors in these models develop in the native microenvironment in immunocompetent mice and have been shown to faithfully mimic human tumorigenesis and responses to therapy. Despite the availability of other highly efficient recombinase-based approaches, mouse models of cancer initiated by recombinases have generally used Cre to mutate genes in tumor parenchymal cells, ruling out the possibility that Cre can be used to genetically modify tumor stromal cells.

**Results**

To develop a dual-recombinase system that would enable modification of different genes in tumor parenchymal cells and stromal cells, the authors of this study generated a *FRT*-flanked allele of the tumor suppressor *p53* that can be deleted by Flp recombinase. They show that efficient deletion of *p53* by FlpO impairs the ability of cells to respond to genotoxic stress and leads to genetic instability. To validate their system in vivo, the authors crossed mice carrying the *FRT*-flanked *p53* allele with mice carrying a Flp-inducible allele of oncogenic *Kras* to create compound conditional mutant mice. Injection of an adenovirus expressing FlpO recombinase initiated primary soft-tissue sarcomas and lung adenocarcinomas after as little as 8 weeks.

**Implications and future directions**

This new mouse model, in which primary tumors can be induced using FlpO recombinase, can be used in combination with the growing number of *loxP*-flanked alleles and tissue-specific Cre drivers to assess the effects of modifying specific genes in tumor stromal cells. Thus, this dual recombinase system will be a powerful tool for investigating the mechanisms by which the tumor microenvironment contributes to cancer development, progression and response to therapy.

Micro-CT scans
--------------

The computerized tomography (CT) data were acquired by X-RAD 225Cx (Precision X-ray, North Branford, CT) using 40 kVp X-rays with 2.5 mA current. Tumor volumes were calculated with Amira image analysis software (TGS, San Diego, CA).
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